REGENERON PHARMACEUTICALS, INC. REGN

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Last close 805.02 2026-10-23
Market cap $82.76B estimated share count
52-week range 575.93 - 859.34

Valuation FY2025 figures against the last close

P/S5.8x
P/E19.4x
P/FCF20.3x
EV/EBITDA18.5x
Dividend yield0.4%
Diluted EPS41.48

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $14.34B$14.20B$13.12B$12.17B$16.07B$8.50B$6.56B$5.15B$5.87B$4.86B
Cost of revenue ——————$402.8M$237.5M$202.5M$194.6M
Gross profit ——————$6.15B$4.91B$5.67B$4.67B
R&D $5.85B$5.13B$4.44B$3.59B$2.86B$2.65B$2.45B$1.47B$2.08B$2.05B
SG&A $2.70B$2.95B$2.63B$2.12B$1.82B$1.35B$1.34B$1.13B$1.32B$1.18B
Total operating expenses $10.77B$10.21B$9.07B$7.43B$7.12B$4.92B$4.35B$2.61B$3.79B$3.53B
Operating income $3.58B$3.99B$4.05B$4.74B$8.95B$3.58B$2.21B$2.53B$2.08B$1.33B
Interest expense $43.8M$55.2M$73.0M$59.4M$57.3M$56.9M$30.2M$28.2M$25.1M$7.2M
Pre-tax income $5.23B$4.78B$4.20B$4.86B$9.33B$3.81B$2.43B$2.55B$2.08B$1.33B
Income tax $725.8M$367.3M$245.7M$520.4M$1.25B$297.2M$313.3M$109.1M$880.0M$434.3M
Net income $4.50B$4.41B$3.95B$4.34B$8.08B$3.51B$2.12B$2.44B$1.20B$895.5M
EPS, basic 43.0740.9037.0540.5176.4032.6519.3822.6511.278.55
EPS, diluted 41.4838.3434.7738.2271.9730.5218.4621.2910.347.70
Shares, diluted (wtd. avg.) 108.6M115.1M113.7M113.5M112.2M115.1M114.6M114.8M115.9M116.3M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $3.12B$2.49B$2.73B$3.12B$2.90B$2.21B$1.63B$1.48B$825.2M$547.7M
Short-term investments $5.49B$6.52B$8.11B$4.64B$2.81B$1.39B$1.60B$1.34B$596.8M$503.5M
Receivables $5.74B$6.21B$5.67B$5.33B$6.04B$4.11B$2.10B$1.72B$1.54B$1.34B
Inventory $3.20B$3.09B$2.58B$2.40B$1.95B$1.92B$1.42B$1.15B$726.1M$399.4M
Total current assets $18.02B$18.66B$19.48B$15.88B$14.01B$9.78B$7.69B$6.45B$4.33B$3.18B
Property, plant and equipment ———————$2.58B$2.36B$2.08B
Other intangibles $1.26B$1.15B$1.04B$915.5M$6.7M—————
Total assets $40.56B$37.76B$33.08B$29.21B$25.43B$17.16B$14.81B$11.73B$8.76B$6.97B
Accounts payable $939.0M$789.5M$606.6M$589.2M$564.0M$475.5M$418.1M$218.2M$178.2M$879.1M
Total current liabilities $4.37B$3.94B$3.42B$3.14B$3.93B$2.70B$2.10B$1.44B$1.14B$1.24B
Long-term debt $1.99B$1.98B$1.98B$1.98B$1.98B$1.98B$0———
Total liabilities $9.30B$8.41B$7.11B$6.55B$6.67B$6.14B$3.72B$2.98B$2.62B$2.52B
Retained earnings $35.80B$31.67B$27.26B$23.31B$18.97B$10.89B$7.38B$5.25B$2.95B$1.75B
Total equity $31.26B$29.35B$25.97B$22.66B$18.77B$11.03B$11.09B$8.76B$6.14B$4.45B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $4.98B$4.42B$4.59B$5.01B$7.08B$2.62B$2.43B$2.20B$1.31B$1.49B
Depreciation and amortisation $543.7M$482.9M$421.0M$341.4M$286.2M$235.9M$210.3M$148.2M$145.5M$104.7M
Stock-based compensation $993.7M$982.8M$885.0M$725.0M$601.7M$432.0M$464.3M$427.4M$507.3M$559.9M
Capital expenditure $898.4M$755.9M$718.6M$590.1M$551.9M$614.6M$429.6M$383.1M$272.6M$511.9M
Investing cash flow -$629.1M-$2.47B-$3.19B-$3.78B-$5.38B-$70.6M-$2.03B-$1.46B-$1.01B-$1.05B
Financing cash flow -$3.72B-$2.20B-$1.79B-$1.01B-$1.01B-$1.97B-$252.1M-$77.1M-$24.4M-$700.5M
Dividends paid $370.3M$0$0———————
Buybacks $3.44B$2.60B$2.23B$2.08B$1.65B$5.85B$275.9M$4.4M$0$0

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001308179-26-000340.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 5B 10B 15B 20B Revenue, FY2016: 4.9B Gross profit, FY2016: 4.7B Net income, FY2016: 895.5M Revenue, FY2017: 5.9B Gross profit, FY2017: 5.7B Net income, FY2017: 1.2B Revenue, FY2018: 5.1B Gross profit, FY2018: 4.9B Net income, FY2018: 2.4B Revenue, FY2019: 6.6B Gross profit, FY2019: 6.2B Net income, FY2019: 2.1B Revenue, FY2020: 8.5B Net income, FY2020: 3.5B Revenue, FY2021: 16.1B Net income, FY2021: 8.1B Revenue, FY2022: 12.2B Net income, FY2022: 4.3B Revenue, FY2023: 13.1B Net income, FY2023: 4B Revenue, FY2024: 14.2B Net income, FY2024: 4.4B Revenue, FY2025: 14.3B Net income, FY2025: 4.5B FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $4.86B $5.87B $5.15B $6.56B $8.50B $16.07B $12.17B $13.12B $14.20B $14.34B
Gross profit $4.67B $5.67B $4.91B $6.15B — — — — — —
Net income $895.5M $1.20B $2.44B $2.12B $3.51B $8.08B $4.34B $3.95B $4.41B $4.50B

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Results announced Item 2.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%